Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author SASSE, Andre Deeke
REIS, Rodolfo Borges dos
NOGUEIRA, Lucas Mendes
MALUF, Fernando Cotait
HERCHENHORN, Daniel
SMALETZ, Oren
LIMA, Volney Soares
SCHUTZ, Fabio
BASTOS, Diogo FMUSP-HC
WIERMANN, Evanius Garcia
MORBECK, Igor Alexandre Protzner
JARDIM, Leonardo Fontes
SOUZA, Vinicius Carrera
CARVALHO, Icaro Thiago
LEITE, Elton Trigo Teixeira
NARDOZZA JR., Archimedes
POMPEO, Antonio Carlos Lima
BRETAS, Francisco
LEAL, Marcos Lima de Oliveira
SADI, Marcus Vinicius
PONTE, Jose Ricardo Tuma da
CARVALHAL, Gustavo F.
dc.date.issued 2019
dc.identifier.citation INTERNATIONAL BRAZ J UROL, v.45, n.3, p.449-458, 2019
dc.identifier.issn 1677-5538
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/32559
dc.description.abstract Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers. The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The first Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of differ-ent technologies is a big challenge, especially in the Sistema Unico de Saude (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clini-cal Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.
dc.description.sponsorship · Janssen
dc.language.iso eng
dc.publisher BRAZILIAN SOC UROL
dc.relation.ispartof International Braz J Urol
dc.rights openAccess
dc.subject Prostatic Neoplasms; Therapeutics; Consensus
dc.subject.other continuous androgen deprivation; increased survival; plus prednisone; recommendations; intermittent; mitoxantrone; abiraterone; trials
dc.title Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
dc.type article
dc.rights.holder Copyright BRAZILIAN SOC UROL
dc.identifier.doi 10.1590/S1677-5538.IBJU.2018.0798
dc.identifier.pmid 31038861
dc.type.category review
dc.type.version publishedVersion
hcfmusp.author BASTOS, Diogo:HC:ICESP
hcfmusp.author.external · SASSE, Andre Deeke:Grp SONHE, Oncol, Campinas, SP, Brazil
· REIS, Rodolfo Borges dos:Univ Sao Paulo, Dept Urol, Campus Ribeirao Preto, Ribeirao Preto, SP, Brazil
· NOGUEIRA, Lucas Mendes:Univ Fed Minas Gerais, Div Urol, Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Dept Cirurgia Hosp Clin, Belo Horizonte, MG, Brazil
· MALUF, Fernando Cotait:Hosp Beneficencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil
· HERCHENHORN, Daniel:Rede DOr Sao Luiz, Rio De Janeiro, Brazil
· SMALETZ, Oren:Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, Brazil
· LIMA, Volney Soares:Oncoctr, Belo Horizonte, MG, Brazil
· SCHUTZ, Fabio:Hosp Beneficencia Portuguesa Sao Paulo, Sao Paulo, SP, Brazil
· WIERMANN, Evanius Garcia:SBOC, Belo Horizonte, MG, Brazil
· MORBECK, Igor Alexandre Protzner:Clin AMO, Salvador, BA, Brazil
· JARDIM, Leonardo Fontes:ICESP, Dept Oncol, Sao Paulo, SP, Brazil
· SOUZA, Vinicius Carrera:SBOC, Belo Horizonte, MG, Brazil
· CARVALHO, Icaro Thiago:Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, Brazil
· LEITE, Elton Trigo Teixeira:Hosp Sirio Libanes, Sao Paulo, SP, Brazil
· NARDOZZA JR., Archimedes:Univ Fed Sao Paulo UNIFESP, Dept Urol & Cirurgia, Sao Paulo, SP, Brazil
· POMPEO, Antonio Carlos Lima:Fac Med ABC, Urol, Santo Andre, SP, Brazil
· BRETAS, Francisco:Hosp Mater Dei, Belo Horizonte, MG, Brazil
· LEAL, Marcos Lima de Oliveira:Univ Fed Bahia UFBA, Dept Urol, Salvador, BA, Brazil
· SADI, Marcus Vinicius:Univ Fed Sao Paulo UNIFESP, Dept Urol & Cirurgia, Sao Paulo, SP, Brazil
· PONTE, Jose Ricardo Tuma da:Univ Estado Para UEPA, Dept Urol, Belem, PA, Brazil
· CARVALHAL, Gustavo F.:Pontificia Univ Catolica Rio Grande Sul PUC RS, Div Urol, Porto Alegre, RS, Brazil; Pontificia Univ Catolica Rio Grande Sul PUC RS, Dept Cirurgia, Porto Alegre, RS, Brazil
hcfmusp.origem.id WOS:000469040400005
hcfmusp.origem.id 2-s2.0-85067268412
hcfmusp.origem.id SCIELO:S1677-55382019000300449
hcfmusp.publisher.city RIO DE JANEIRO
hcfmusp.publisher.country BRAZIL
hcfmusp.relation.reference · Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
· Chi BH, 2018, YONSEI MED J, V59, P389, DOI 10.3349/ymj.2018.59.3.389
· Dalesio O, 2000, LANCET, V355, P1491
· De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
· de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
· Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706
· Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
· Gillatt D, 2006, J CANCER RES CLIN, V132, pS17, DOI 10.1007/s00432-006-0133-5
· Hershman DL, 2016, JAMA ONCOL, V2, P453, DOI 10.1001/jamaoncol.2015.4655
· Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
· Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299
· INCA. Instituto Nacional do Cancer, 2018, EST 2018 INC CANC BR
· James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900
· James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
· Kolinsky M, 2016, EUR UROL, V69, P841, DOI 10.1016/j.eururo.2015.10.052
· Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657
· Loblaw DA, 2012, J CLIN ONCOL, V30, P3136, DOI 10.1200/JCO.2012.42.0489
· Metcalfe MJ, 2017, UROL ONCOL-SEMIN ORI, V35, P125, DOI 10.1016/j.urolonc.2017.01.001
· Nishiyama T., 2014, UROL ONCOL, V32
· Nishiyama T, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.03.007
· Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
· Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7
· Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
· Sasse AD, 2017, INT BRAZ J UROL, V43, P407, DOI [10.1590/S1677-5538.IBJU.2016.0490, 10.1590/s1677-5538.ibju.2016.0490]
· Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
· Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
· Schmid S, 2015, ANN ONCOL, V26, P2221, DOI 10.1093/annonc/mdv326
· Sun MX, 2016, JAMA ONCOL, V2, P500, DOI 10.1001/jamaoncol.2015.4917
· Vale CL, 2016, LANCET ONCOL, V17, pE46
· Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1
dc.description.index MEDLINE
dc.identifier.eissn 1677-6119
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics